Lipitas Gold 75mg/10mg/75mg Capsule is a combination pharmaceutical formulation containing Aspirin (75mg), Rosuvastatin (10mg), and Clopidogrel (75mg), designed for the prevention and management of cardiovascular diseases. Aspirin, a well-known antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 production and preventing platelet aggregation. Rosuvastatin, a potent statin, acts by inhibiting HMG-CoA reductase, leading to decreased cholesterol synthesis and improved lipid profiles, which helps in reducing atherosclerotic plaque formation. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP receptor on platelet cell membranes, further preventing platelet activation and aggregation. This combination is primarily indicated for patients at high risk of thrombotic events such as myocardial infarction, stroke, and peripheral arterial disease, particularly in those with dyslipidemia and a history of cardiovascular complications. The synergistic effect of these agents provides comprehensive cardiovascular protection by addressing multiple pathogenic pathways. Lipitas Gold should be administered under strict medical supervision, considering potential contraindications and drug interactions. Regular monitoring of lipid levels, platelet function, and liver enzymes is recommended to ensure therapeutic efficacy and safety. This medication is not suitable for patients with active bleeding, hypersensitivity to any component, or severe hepatic impairment.